Sam Brusco, Associate Editor11.01.22
W.L. Gore & Associates (Gore) has achieved the first implants of its investigational GORE VIAFORT vascular stent as part of its recently initiated GORE VIAFORT device pivotal clinical study to treat inferior vena cava (IVC) occlusive disease with or without iliofemoral vein involvement.
The first-in-human procedures were completed at the Auckland City Hospital in Grafton, Auckland, New Zealand, by interventional radiologist Andrew Holden, MD, Director of Regional Interventional Radiology at the Auckland Regional Public Health Service.
"This first implantation is an important milestone for venous occlusive disease treatment," Dr. Holden told the press. "Right now, there are limited device options indicated for both IVC and iliofemoral venous disease. Implanting the GORE VIAFORT Vascular Stent in patients represents a significant step forward in research."
The VIAFORT vascular stent uses Gore’s expanded polytetrafluoroethylene (PTFE) tech with a single-wound nitinol frame. The clinical study is assessing the device in a treatment range of 10-28 mm diameter for iliofemoral veins and the IVC.
The first-in-human procedures were completed at the Auckland City Hospital in Grafton, Auckland, New Zealand, by interventional radiologist Andrew Holden, MD, Director of Regional Interventional Radiology at the Auckland Regional Public Health Service.
"This first implantation is an important milestone for venous occlusive disease treatment," Dr. Holden told the press. "Right now, there are limited device options indicated for both IVC and iliofemoral venous disease. Implanting the GORE VIAFORT Vascular Stent in patients represents a significant step forward in research."
The VIAFORT vascular stent uses Gore’s expanded polytetrafluoroethylene (PTFE) tech with a single-wound nitinol frame. The clinical study is assessing the device in a treatment range of 10-28 mm diameter for iliofemoral veins and the IVC.